Multiple clinical studies have demonstrated that the promotion of glucosuria by SGLT2 inhibitors (SGLT2is) can substantially alleviate diabetic burden3–6 ensuing in their approval for the treatment of type 2 diabetes mellitus (T2D)7. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.